ANIP - ANI Pharmaceuticals Corp Total Debt to Capital

This price chart based on the separate_debt_total_eq metric confirms the financial stability of ANI Pharmaceuticals (ANIP), where the metric stands at 1.06. The business relies on its own network of sterile plants and hubs in the US, ensuring stable product output. ANI Pharmaceuticals (ANIP) is betting on complex generics and rare pathologies, utilizing profits from its core asset to fund M&A transactions. The development of contract manufacturing and branded drugs helps mitigate the risks of dependence on standard generics.

ANI Pharmaceuticals maintains its status as a stable supplier of niche generics, ensuring the accessibility of therapies within critical segments of US healthcare. An analysis of the debt-to-equity ratio allows for an assessment of financial leverage by measuring the proportion of borrowed funds relative to net assets to identify default risks amid rising rates and confirm the long-term sustainability of the business model.